Ajovy’s success in migraine repeated in the Chinese study

Market Event Summary

Ajovy (fremanezumab), a leading CGRP-targeting monoclonal antibody, has consistently proven its value in migraine prophylaxis across major markets. Now, with positive Phase 3 trial results in China, Teva is set to redefine migraine treatment in a market historically underserved by effective options.

Key highlights:

1. Breakthrough results from China’s phase 3 study

Ajovy significantly reduced monthly migraine days in both episodic and chronic migraine patients.
Teva’s success follows a long history of unmet needs in China, where traditional prophylactic treatments have shown limited efficacy.

2. Unique differentiators

Offers both monthly and quarterly subcutaneous dosing, catering to patient preferences for convenience.
The subcutaneous delivery method provides an edge over competitors like Vyepti, which requires intravenous administration.

3. Market outlook and growth

Ajovy is expected to secure NMPA approval by late 2025, becoming the third anti-CGRP monoclonal antibody available in Mainland China.
With a rapidly expanding migraine treatment market projected to quintuple by 2032, Ajovy is well-positioned to capture significant market share.

Complete the form below to download the report.